Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Hawkins, Douglas S.; Spunt, Sheri L.; Skapek, Stephen X.

doi:10.1002/pbc.24435

Cited by 160 publications

(170 citation statements)

References 115 publications

(152 reference statements)

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Pediatric soft-tissue tumors may be present as rhabdomyosarcoma, nonrhabdomyosarcoma soft-tissue sarcomas compromising various mesenchymal malignancies, or desmoid tumors (41). The staging of soft-tissue tumors requires an assessment of primary tumor size, location, and invasiveness.…”

Section: Soft-tissue Tumorsmentioning

confidence: 99%

Potential Pediatric Applications of PET/MR

et al. 2014

View full text Add to dashboard Cite

Medical imaging with multimodality and whole-body technologies has continuously improved in recent years. The advent of combined modalities such as PET/CT and PET/MR offers new tools with an exact fusion of molecular imaging and high-resolution anatomic imaging. For noninvasive pediatric diagnostics, molecular imaging and whole-body MR have become important, especially in pediatric oncology. Because it has a lower radiation exposure than PET/CT, combined PET/MR is expected to be of special use in pediatric diagnostics. This review focuses on possible pediatric applications of PET/MR hybrid imaging, particularly pediatric oncology and neurology but also the diagnosis of infectious or inflammatory diseases.

show abstract

Section: Soft-tissue Tumorsmentioning

confidence: 99%

Potential Pediatric Applications of PET/MR

et al. 2014

View full text Add to dashboard Cite

show abstract

“…They have an excellent outcome (2-year event-free survival [EFS] 88%, OS 98%) with short duration therapy with low cumulative alkylator dose [20] . Further classification is done by COG to stratify those patients, of which a patient subset might be futurely transferred to intermediate risk group [21,22] .…”

Section: Discussionmentioning

confidence: 99%

Rhabdomyosarcoma in adolescents: A CCHE experience

Moussa

Nadi

Zomor

et al. 2015

JST

View full text Add to dashboard Cite

Objective and aim: A lower outcome of rhabdomyosarcoma in elder children and young adolescents is increasingly recognized. Our aim was to focus on the outcome of elder children and adolescents with rhabdomyosarcoma treated at our Center (CCHE). Patients and methods:Patients between the age 10 and 18 years diagnosed as rhabdomyosarcoma and treated according to IRS -IV, or IRS V protocols determined according to site, stage, and age at diagnosis.Results: Thirty-two children were recruited at Children's Cancer Hospital-Egypt. They were 12 females (37.5%) and 20 males (62.5%), with a mean age of 12.8y. The mean follow up period was 29.4 months (July 2007 till December 2012). Seventeen patient, were allocated to IRS-IV, and 15 patient to IRS-V. The overall survival and failure free survival were 59.1% and 40.4% respectively. Forty six percent of patients had alveolar pathology, 68.8% presented with tumors at unfavorable sites; 37.5% had metastases at presentation; and 21.9% had intracranial extension at presentation. Risk status, clinical grouping and tumor size affected FFS significantly. Local control was done by radiation therapy in 62.5%, surgery alone in 9.4%, and both radiation and surgery in 25%. Conclusion:The outcome of adolescent group showed inferior results compared to younger children. More cooperation and knowledge about RMS, in this age category, can help develop more intensive unified management approach for them.

show abstract

“…Группы риска и результаты лечения пациентов детского возраста с рабдомиосаркомой по данным COG (по [7][8][9] Примечание. АРМС/ЭРМС -альвеолярный/эмбриональный вариант рабдомиосаркомы.…”

Section: обоснованиеunclassified

Clinical Significance of Transnasal Endoscopic Surgery in the Treatment of Children With Localized Parameningeal Sarcomas

et al. 2017

View full text Add to dashboard Cite

ОБОСНОВАНИЕСаркомы костей и мягких тканей чаще встречают-ся у пациентов моложе 21 года. Рабдомиосаркома (РМС) -основной гистологический тип сарком дет-ского возраста, который составляет до 6% всех опу-холей у пациентов младше 15 лет. РМС чаще (36%) локализуется в органах головы и шеи. По лока-лизации саркомы головы и шеи разделяют на два анатомических региона -пара-и непараменин-геальный, различающиеся прогнозом заболева-ния. К параменингеальной локализации относятся опухоли, расположенные в полости носа, носоглот-ке, околоносовых пазухах, среднем ухе, височной кости, а также в подвисочной и крылонебной ямках [1]. Другие морфологические варианты сарком мягких тканей параменингеальной локализации и саркомы костей основания черепа составляют не более 1% среди всех злокачественных опухолей детского возраста. Лечебные подходы основаны на проведении полихимиотерапии (ПХТ) в предоперационном периоде и лучевой терапии при чувствительности опухоли к лучевому воздействию.Результаты международных исследовательских групп IRS 1 и COG 2 убедительно доказали влияние на исход лечения детей с РМС таких независимых факторов, как локализация первичной опухоли, размер, инвазия в соседние органы и ткани, а так-же метастатическое поражение региональных лим-фатических узлов и наличие отдаленных метастазов

show abstract

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Cited by 160 publications

References 115 publications

Potential Pediatric Applications of PET/MR

Potential Pediatric Applications of PET/MR

Rhabdomyosarcoma in adolescents: A CCHE experience

Clinical Significance of Transnasal Endoscopic Surgery in the Treatment of Children With Localized Parameningeal Sarcomas

Contact Info

Product

Resources

About